Share

    


Home / Search Results

Search Results

You searched for:

The US has seen a steady decline in the overall incidence of colorectal cancer (CRC) during the past several decades. In 1975, 60 people per 100,000 were diagnosed with colorectal cancer; by 2018, that number had fallen to 34. But overall trends in CRC incidence and outcomes often differ among racial groups and geographic locations. Black Americans are more likely to be diagnosed with CRC than White …
An integrated precision tracking program ensures proper follow-up care and surveillance for survivors of colorectal cancer.
To help address the ongoing prevalence of colorectal cancer, ACCC is inviting its members to submit proposals for quality improvement initiatives in treating metastatic forms of this cancer.
By Diane Mapes For the immunocompromised and those with disease, social distancing and uncertainty are a way of life. Daily walks, gratitude, and dancing help. You’re washing your hands like crazy. Staying six feet away from people with the sniffles. You don’t know if it’s safe to hug your friends or family, or go to work, or what. You don’t even know if you’ll be alive in a year. It’s scary. …
Though the incidence of AIDS-defining cancers has decreased with the use of antiretroviral therapy, numerous studies suggest that non-AIDS-defining cancers (cancers not previously associated with HIV and AIDS) appear to be increasing in incidence.
Colorectal cancer represents 8.3 percent of all new cancer diagnoses in the U.S. In 2016, there were an estimated 1,324,922 people in the U.S. living with colorectal cancer.
As the use of biomarker testing options in the treatment of certain cancers continues to grow, so too do barriers to their use. Underpinning these barriers is a lack of understanding about how biomarker testing works and what impact it can have on selecting the most promising cancer treatment options. Measurable residual disease (also known as “minimal residual disease”) refers to the number of cancer …
The goal of this initiative is to provide guidance for multidisciplinary care teams on how to develop practical biomarker testing protocols for metastatic colorectal cancer.
BiomarkerLIVE ACCC launched BiomarkerLIVE in 2019 with the goal of improving communication about biomarkers and molecular profiling among cancer care teams. Now in its second phase, this project is currently focused on helping cancer providers facilitate the integration of precision medicine into their daily practice. Learn More Biomarker Testing In partnership with Pfizer Global Medical …